Bernard Asselain

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 195 publications

Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.

Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.

Journal: Dermatology and therapy
Published: March 20, 2026

Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.

Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.

Journal: BMJ open
Published: September 04, 2025

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.

Journal: NEJM evidence
Published: June 24, 2025

Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Journal: Clinical pharmacology and therapeutics
Published: May 20, 2025

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Journal: Oncoimmunology
Published: April 15, 2025

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Journal: Nature communications
Published: March 07, 2025

Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study.

Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study.

Journal: EClinicalMedicine
Published: January 21, 2025

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)
Published: October 25, 2024

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

Journal: ESMO open
Published: October 07, 2024

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology
Published: July 25, 2024

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018).

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018).

Journal: ESMO real world data and digital oncology
Published: June 03, 2024

Concomitant medication, comorbidity and survival in patients with breast cancer.

Concomitant medication, comorbidity and survival in patients with breast cancer.

Journal: Nature communications
Published: November 17, 2023
Showing 1-12 of 195

Last Updated: 09/26/2026